Dream – Visualize - Lead

PUBLIC EXPOSE

PT DARYA-VARIA LABORATORIA TbkFairmont Hotel, Jakarta, June 11, 2019

Dream – Visualize - Lead

Topik / Topics :

1. Tinjauan PasarMarket Overview

2. Sekilas tentang DVLDVL at a Glance

3. Tinjauan Bisnis DVL Tahun 2018DVL Business Overview FY 2018

4. Kinerja DVL Kuartal 1-2019 DVL Performance 1st Q-2019

Kondisi UmumGeneral ConditionsKondisi Umum

General Conditions

Ekonomi Indonesia di 2018 tumbuh lebih tinggi dari tahun sebelumnya,dengan nilai inflasi yang terkendali

Indonesian economy in FY 2018 is growing faster than last year, with inflation rate controlled

GPD Growth ( % ) Inflation MAT ( % )

SOURCE: BPS.GO.ID

Kondisi UmumGeneral Conditions

SOURCE: NIELSEN CPS DATA – ADDITIONAL SPENDING +79 FMCG HOMEPANEL – MAT Q4 2017 VS MAT Q4 2018

% GROWTH (SPEND/BUYER)

Secara umum, rumah tangga mempertahankan pengeluaran rutinnya.RT masih mau menambah pengeluaran untuk bersenang-senang dan pemeliharaan

rumah, namun mengurangi pengeluaran untuk kesehatan dan pendidikanIn general, household are maintaining their regular spending.

However HH are still willing to increase Leisure & Housing Related but at the same time they reduce spending in Health & Education.

Kondisi UmumGeneral Conditions

SOURCE: (1) BPS OFFICIAL GOVERNMENT SITE, & NIELSEN RETAIL DATA

Trend FMCG masih terus melambat ; kategori kebutuhan tertier masih bertumbuh, sementara kategori kebutuhan sehari-hari masih belum membaik

The slowing down trend of FMCG industry is still continue; indulgence categories are growing, while daily usage categories are suffering

TOP 20 CATEGORY – VALUE GROWTHFMCG – VALUE & VOLUME GROWTH

Kondisi UmumGeneral ConditionsKondisi Umum

General Conditions

Pasar farmasi Indonesia mengalami pertumbuhan 2% pada MAT Q3 2018;Pasar OTC menurun hampir 9% (IQVIA Combined Audit 3Q 2018).

Indonesian pharmaceutical market has increased to 2.0% in MAT Q3 2018The OTC market largely declined by nearly 9% (IQVIA Combined Audit 3Q 2018).

Source : Combined Audit 3Q18 2 (Combined Audit : Hospital + Pharmacy + Drugstore)

“Menteri Keuangan Sri Mulyani menyebut hasil audit BPKP menunjukkan defisit keuangan pada BPJS Kesehatan tahun lalu mencapai Rp 9,1 triliun. ”

“Ministry of Finance Sri Mulyani mention result of BPKP audit shown last year BPJS Kesehatan budget deficit reach Rp. 9.1 T.” [CNN Indonesia | Selasa, 28/05/2019)

Source: BPJS.go.id

Jaminan Kesehatan NasionalNational Health Insurance

Q1-2019

221mio

(84% coverage)

2018

208mio

2017

188mio

2016

172mio

2015

157mio

2014133mio

SEKILASTENTANG DVL

DVL AT A GL ANCE

1976

FEBRUARI/FEBRUARYPerseroan didirikan

The company established

1994

OKTOBER/OCTOBERPenawaran Umum Perdana

sebanyak sepuluh juta saham

Initial Public Offeringof ten million shares

2001

DESEMBER/DECEMBERFar East Drug (BVI) Co. Ltd.

membeli 17.716.940 saham perseroan

Far East Drug (BVI) Co. Ltd. purchased 17,716,940 shares of the Company

2005

Pabrik Gunung Putri dan Citeureup keduanyamendapatkan sertifikasi GMP strata-A

Both Gunung Putri and Citeureup Plant facilities received strata-A GMP certification

2012

Membukukan Rp 1 Trillion dari total penjualanbisnis Ethical, OTC dan Toll & Export

Registered IDR 1 Trillion combined sales from Ethical, OTC and Toll & Export business

2018

DESEMBER/DECEMBERPenghargaan Halal 2018

untuk Natur-E oleh LPPOM-MUI

Halal Award 2018 for Natur-E given by LPOM-MUI

Bisnis Obat ResepPrescription Business

Bisnis Consumer HealthConsumer Health Business

Bisnis Ekspor& Jasa Toll Manufacturing

Export & Toll Manufacturing Business

Segmen Bisnis UtamaMain Business Segments

Fasilitas ProduksiProduction Facilities

Citeureup, BogorProduk Steril & Padat

Sterile & Solid

Gunung Putri, BogorKapsul Lunak, Cairan, KosmetikSoft Capsule, Liquid, Cosmetic

IKHTISARDVL

DVL HIGHLIGHTS

Peluncuran Produk BaruNew Products Launch

MAY 2018: Natur-E Advanced Face Series

MAR 2018: Orvast dan Atorvastatain NOV 2018: Epifri

SEP 2018: Nomatic dan Pregabalin

Kegiatan PemasaranMarketing Activities

Medical Congress

Scientific Seminars TVC

On the ground Activities

TINJAUAN BISNISDVL TAHUN 2018

D V L B U S I N E S S O V E R V I E W

F Y 2 0 1 8

Kinerja DVL Tahun 2018DVL Performance FY 2018

Bisnis Obat Resep(Prescription Business)

Bisnis Obat Bebas(Consumer Health Business)

Bisnis Export & Jasa Toll Manufacturing(Export & Toll Manufacturing Business)

580 M 705 M 415 M

8 %

TOTALPertumbuhan

Growth

8%

1.700 MPenjualan Bersih

Net Sales

-5.5 % 41.7%

2017 2018

894 925

LAPORAN LABA RUGI STATEMENT OF PROFIT OR LOSS

2017 2018

220 267

2017 2018

162 201

Marjin Laba BersihNet Income Margin

201710,3%

201811,8%

Laba BrutoGross Income

Laba UsahaOperating Income

Laba BersihNet Income

2017 2018

Laba Bersih per Saham(Rupiah Penuh)

Net Income per Share(Full Rupiah)

145 180

(dalam miliar Rupiah)(in billion Rupiah)

3.5% 21.5% 23.7% 24%% Pertumbuhan% Growth

2017 2018

1.641 1.683

2017 2018

1.176 1.203

2017 2018

525 483

Total AsetTotal Assets

Aset LancarCurrent Assets

Total LiabilitasTotal Liabilities

2017 2018

EkuitasEquity

1.116 1.200

(dalam miliar Rupiah)(in billion Rupiah)

2.6% 2% -8% 7,5%% Pertumbuhan% Growth

LAPORAN POSISI KEUANGAN STATEMENT OF FINANCIAL POSITION

Arus kas dari operasionalCash flows from operations

2018

2017

Decrease: 88,5%

Arus kas untuk aktivitas investasiCash flows used in investing activities

2018

2017

Increase: 43%

Arus kas untuk aktivitas pendanaanCash flows used in financing activities

2018

2017

Increase: 7%

LAPORAN ARUS KASSTATEMENT OF CASH FLOWS

DVL PERFORMANCE

1 s t Q - 2019

KINERJA DVLKUARTAL 1-2019

Kinerja Kuartal 1-2019Q1 2019 Performance

I. Total Penjualan Bersih DVL sebesar Rp 482 miliar- DVL tumbuh sebesar 12%

II. Apa yang mendukung kinerja bisnis?- Pertumbuhan Ekspor dan Jasa Toll

Manufacturing

III. Tantangan bisnis- Bisnis obat resep- Bisnis obat bebas

I. Total DVL Net Sales at Rp 482 bio- DVL grew by 12%

II. What drove the business?

- Export and Toll Manufacturing growth

III. Business challenges

- Prescription drugs

- Consumer Health

IV. Keuangan :

- Laba Bruto, Laba Usaha & Laba Bersih DVL

tetap terjaga

IV. Financials :

- DVL Gross Income, Operating Income &

Net Profit are on track

V. Program Sampai Dengan Akhir Tahun yang

terencanaV. Balance Year Program in place

SESITANYA JAWAB

Q U E S T I O N S A N D A N S W E R S

DVL PUBL IC EXPOSE